IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VALDAGNI, RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.393
NA - Nord America 10.684
AS - Asia 9.108
SA - Sud America 900
AF - Africa 231
OC - Oceania 145
Continente sconosciuto - Info sul continente non disponibili 9
Totale 34.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.346
DE - Germania 6.293
SG - Singapore 2.851
CN - Cina 2.678
IT - Italia 1.900
GB - Regno Unito 1.515
SE - Svezia 784
HK - Hong Kong 770
RU - Federazione Russa 760
VN - Vietnam 715
BD - Bangladesh 711
BR - Brasile 658
FR - Francia 451
IN - India 378
NL - Olanda 353
IE - Irlanda 340
CA - Canada 227
JP - Giappone 176
FI - Finlandia 161
ID - Indonesia 155
ES - Italia 151
TR - Turchia 136
AU - Australia 131
DK - Danimarca 105
KR - Corea 97
BE - Belgio 83
CI - Costa d'Avorio 82
UA - Ucraina 73
AT - Austria 69
CH - Svizzera 65
PL - Polonia 64
AR - Argentina 59
MX - Messico 58
PH - Filippine 52
CO - Colombia 48
IQ - Iraq 47
RO - Romania 45
CL - Cile 44
PK - Pakistan 43
TW - Taiwan 43
TH - Thailandia 41
MY - Malesia 34
ZA - Sudafrica 32
EC - Ecuador 29
NO - Norvegia 29
GR - Grecia 25
IR - Iran 25
EG - Egitto 22
MA - Marocco 21
SA - Arabia Saudita 21
CZ - Repubblica Ceca 20
PE - Perù 20
PT - Portogallo 19
VE - Venezuela 19
TN - Tunisia 18
UZ - Uzbekistan 17
KE - Kenya 16
JO - Giordania 15
AE - Emirati Arabi Uniti 13
JM - Giamaica 13
BG - Bulgaria 12
HU - Ungheria 12
IL - Israele 11
NZ - Nuova Zelanda 11
RS - Serbia 11
CR - Costa Rica 10
UY - Uruguay 10
EU - Europa 9
SK - Slovacchia (Repubblica Slovacca) 9
AZ - Azerbaigian 8
DZ - Algeria 7
KZ - Kazakistan 7
LB - Libano 7
LT - Lituania 7
NP - Nepal 7
BO - Bolivia 6
EE - Estonia 6
ET - Etiopia 6
GE - Georgia 6
LK - Sri Lanka 6
LV - Lettonia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AL - Albania 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
OM - Oman 5
PY - Paraguay 5
SC - Seychelles 5
BH - Bahrain 4
BY - Bielorussia 4
HR - Croazia 4
KG - Kirghizistan 4
MD - Moldavia 4
KH - Cambogia 3
KW - Kuwait 3
MO - Macao, regione amministrativa speciale della Cina 3
MU - Mauritius 3
PA - Panama 3
PR - Porto Rico 3
SN - Senegal 3
Totale 34.416
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 5.703
Singapore 1.585
Ashburn 1.302
Southend 1.173
Chandler 998
Hong Kong 662
San Jose 656
Milan 641
Houston 586
Dallas 421
Beijing 399
Princeton 386
Santa Clara 376
Council Bluffs 351
Fairfield 351
Dublin 330
Wilmington 294
Los Angeles 251
New York 243
Seattle 207
Ho Chi Minh City 199
Ann Arbor 185
Woodbridge 178
Lauterbourg 176
Des Moines 174
Dearborn 171
Cambridge 163
Hanoi 160
Shanghai 156
Buffalo 151
Redwood City 147
Moscow 146
Guangzhou 132
Nanjing 122
Bengaluru 119
Columbus 107
Jakarta 107
Helsinki 97
The Dalles 95
Phoenix 91
Grafing 90
Rome 85
Abidjan 82
Boardman 82
Munich 82
São Paulo 79
Tokyo 78
Jinan 73
Shenyang 69
Toronto 69
Cangzhou 68
Amsterdam 64
Central District 63
Fuzhou 62
Berlin 59
Istanbul 59
Brussels 55
Nuremberg 51
Hebei 49
Shenzhen 48
Tianjin 47
Changsha 45
London 45
Dong Ket 43
Seoul 41
Chicago 40
Da Nang 37
Hangzhou 37
Mumbai 36
Naples 36
Rotterdam 35
San Diego 34
Eitensheim 31
Madrid 31
Montreal 31
Nanchang 31
Vienna 31
Zhengzhou 30
Turin 29
Hefei 28
Atlanta 27
Falls Church 26
Jiaxing 26
Wuhan 26
Bologna 25
Haiphong 25
San Francisco 25
Warsaw 25
Melbourne 24
Washington 24
Bangkok 23
Chengdu 23
Taipei 23
Oslo 22
Redmond 22
Boston 21
Rio de Janeiro 21
Suzhou 21
Bari 20
Mountain View 20
Totale 22.345
Salva come PNG Salva come JPEG
Nome #
Expert consensus document: Semantics in active surveillance for men with localized prostate cancer-results of a modified Delphi consensus procedure 823
Management of Patients with Advanced Prostate Cancer : the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 744
Understanding urinary toxicity after radiotherapy for prostate cancer: First steps forward 593
Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study) 585
The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date 521
MariX, an advanced MHz-class repetition rate X-ray source for linear regime time-resolved spectroscopy and photon scattering 460
miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C epsilon 423
Linee guida carcinoma della prostata : AIRO, 2016 407
T2w-MRI signal normalization affects radiomics features reproducibility 400
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 399
Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer 370
LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation 366
REQUITE : a prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer 341
MiR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCϵ and ZEB1 inhibition 332
Eleven-year management of prostate cancer patients on active surveillance : what have we learned? 331
How does active surveillance for prostate cancer affect quality of life? A systematic review 321
Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 306
A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients 294
Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRC IG 14300) 293
Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations 292
A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study 283
A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort 280
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study : patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 279
Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy 279
Modelling radiation‐induced salivary dysfunction during IMRT and chemotherapy for nasopharyngeal cancer patients 264
miR-21: an oncomir on strike in prostate cancer 255
Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification : Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy 253
'Act on oncology' as a new comprehensive approach to assess prostate cancer centres : Method description and results of a pilot study 251
Treatment decision-making process of men with newly diagnosed localized prostate cancer : the role of multidisciplinary approach in patient engagement 246
Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy 244
SPOP deregulation improves the radiation response of prostate cancer models by impairing DNA damage repair 242
COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy 242
Prostate Cancer Unit Initiative in Europe : a position paper by the European School of Oncology 241
Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with cyberknife 240
Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients 239
Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study) 234
Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy 232
Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer : results of a cohort study 232
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors 231
Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients 231
Mixed-beam approach for high-risk prostate cancer : Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300) 230
Prediction of grade reclassification of prostate cancer patients on active surveillance through the combination of a three-mirna signature and selected clinical variables 230
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity 227
Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients : Clinical Evaluation of an Italian Experience 226
Patient's choice of observational strategy for early-stage prostate cancer 223
Moderate hypofractionation with simultaneous integrated boost in prostate cancer: long-term results of a phase I-II study 220
Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy : Results of a multicenter randomized placebo-controlled dose-finding phase 2 study 219
Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer : Bowel dose-volume effect quantification in a multicentric cohort study 218
Almost one year of COVID-19 pandemic : how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study 215
miR-205 regulates basement membrane deposition in human prostate: implications for cancer development 213
Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers 210
Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer : New Insights From External Independent Validation 208
Comment on "objective assessment in digital images of skin erythema caused by radiotherapy" [Med. Phys. 42, 5568-5577 (2015)] 207
Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors 206
An accurate method to quantify breathing-induced prostate motion for patients implanted with electromagnetic transponders 206
Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer 205
Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey 205
Older age and comorbidity in breast cancer : is RT alone the new therapeutic frontier? 202
Potential of the Stromal Matricellular Protein Periostin as a Biomarker to Improve Risk Assessment in Prostate Cancer 200
Adaptation and validation of an Italian version of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) 200
Back to (new) normality-A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2 199
Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials 197
Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation 195
Active surveillance for low-risk prostate cancer Worldwide : The PRIAS study 195
Cancer of the prostate 194
Hypofractionated whole-breast radiotherapy in large breast size patients : is it really a resolved issue? 194
MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells 191
Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab : acute toxicities in triple-negative breast cancer 189
Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients : results from a large pooled population 186
Texture analysis of T1-w and T2-w MR images allows a quantitative evaluation of radiation-induced changes of internal obturator muscles after radiotherapy for prostate cancer 186
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 185
Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study 185
Interobserver variability (between radiation oncologist and radiation therapist) in tumor bed contouring after breast-conserving surgery 184
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium 184
High quality surface reconstruction in radiotherapy : Cross-sectional contours to 3D mesh using wavelets 182
miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression 182
Long term rectal function after high-dose prostatecancer radiotherapy : results from a prospective cohort study 181
Physics aspects of prostate tomotherapy : Planning optimization and image-guidance issues 178
MiR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts 177
Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy : Planning data and toxicity results of a Phase I-II study 174
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy : incidence of management changes 173
First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy 173
Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients 172
Active surveillance for low-risk prostate cancer : developments to date 171
Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? 169
External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort 169
Living with untreated prostate cancer : Predictors of quality of life 168
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 168
Predictors of patient-reported incontinence at adjuvant/salvage radiotherapy after prostatectomy : Impact of time between surgery and radiotherapy 168
Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy 167
Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance 166
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study) 166
Correlation between surrogates of bladder dosimetry and dose-volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy 164
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees 163
Prostate cancer : ESMO consensus conference guidelines 2012 163
Dose-volume effects for normal tissues in external radiotherapy : pelvis 162
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees 162
Follow-up of elderly patients with urogenital cancers : evaluation of geriatric care needs and related actions 161
Active surveillance for low-risk prostate cancer 160
Multipeptide vaccination in cancer patients 159
Totale 24.931
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.192
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.192
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.485 133 85 82 136 218 162 283 134 201 203 145 703
2022/20233.126 425 337 301 353 283 557 86 206 289 53 158 78
2023/20245.715 80 140 111 89 373 211 854 971 380 768 888 850
2024/20256.502 794 821 638 740 427 233 161 458 241 452 483 1.054
2025/202610.325 828 542 835 758 1.065 725 1.257 480 1.187 683 1.152 813
2026/2027239 239 0 0 0 0 0 0 0 0 0 0 0
Totale 35.737